The Apex Times
Above the Noise
Business Wire
BusinessGoldman Sachs and JPMorgan Chase both raise dividends, prompting fresh debate over which large bank offers the better valueThe Apex TimesBusinessNike stock’s sharp underperformance is drawing fresh bullish arguments, but details remain thinThe Apex TimesBusinessModerna’s Phase 3 cancer vaccine win and Nasdaq-100 inclusion highlight shift toward oncologyThe Apex TimesBusinessLeidos (LDOS) wins $56 million Naval Health Research Center award and extends UK defence logistics workThe Apex TimesBusinessDefense Stocks Watch: RTX Adds Counter-Drone Business as AeroVironment Announces International Deals and Palantir Moves With New AI VentureThe Apex TimesBusinessNavy C-130J-30 Delivery Points to Continued Progress for Lockheed’s TACAMO Mission, Investors Watch for Follow-ThroughThe Apex TimesBusinessMastercard pushes a stablecoin-ready payments “switchboard,” aiming to make crypto rails easier for banksThe Apex TimesBusinessLockheed Martin’s missile backlog and new PAC-3 Edge interceptor add momentum as investors weigh valuationThe Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex TimesBusinessGoldman Sachs and JPMorgan Chase both raise dividends, prompting fresh debate over which large bank offers the better valueThe Apex TimesBusinessNike stock’s sharp underperformance is drawing fresh bullish arguments, but details remain thinThe Apex TimesBusinessModerna’s Phase 3 cancer vaccine win and Nasdaq-100 inclusion highlight shift toward oncologyThe Apex TimesBusinessLeidos (LDOS) wins $56 million Naval Health Research Center award and extends UK defence logistics workThe Apex TimesBusinessDefense Stocks Watch: RTX Adds Counter-Drone Business as AeroVironment Announces International Deals and Palantir Moves With New AI VentureThe Apex TimesBusinessNavy C-130J-30 Delivery Points to Continued Progress for Lockheed’s TACAMO Mission, Investors Watch for Follow-ThroughThe Apex TimesBusinessMastercard pushes a stablecoin-ready payments “switchboard,” aiming to make crypto rails easier for banksThe Apex TimesBusinessLockheed Martin’s missile backlog and new PAC-3 Edge interceptor add momentum as investors weigh valuationThe Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex TimesBusinessGoldman Sachs and JPMorgan Chase both raise dividends, prompting fresh debate over which large bank offers the better valueThe Apex TimesBusinessNike stock’s sharp underperformance is drawing fresh bullish arguments, but details remain thinThe Apex TimesBusinessModerna’s Phase 3 cancer vaccine win and Nasdaq-100 inclusion highlight shift toward oncologyThe Apex TimesBusinessLeidos (LDOS) wins $56 million Naval Health Research Center award and extends UK defence logistics workThe Apex TimesBusinessDefense Stocks Watch: RTX Adds Counter-Drone Business as AeroVironment Announces International Deals and Palantir Moves With New AI VentureThe Apex TimesBusinessNavy C-130J-30 Delivery Points to Continued Progress for Lockheed’s TACAMO Mission, Investors Watch for Follow-ThroughThe Apex TimesBusinessMastercard pushes a stablecoin-ready payments “switchboard,” aiming to make crypto rails easier for banksThe Apex TimesBusinessLockheed Martin’s missile backlog and new PAC-3 Edge interceptor add momentum as investors weigh valuationThe Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex TimesBusinessGoldman Sachs and JPMorgan Chase both raise dividends, prompting fresh debate over which large bank offers the better valueThe Apex TimesBusinessNike stock’s sharp underperformance is drawing fresh bullish arguments, but details remain thinThe Apex TimesBusinessModerna’s Phase 3 cancer vaccine win and Nasdaq-100 inclusion highlight shift toward oncologyThe Apex TimesBusinessLeidos (LDOS) wins $56 million Naval Health Research Center award and extends UK defence logistics workThe Apex TimesBusinessDefense Stocks Watch: RTX Adds Counter-Drone Business as AeroVironment Announces International Deals and Palantir Moves With New AI VentureThe Apex TimesBusinessNavy C-130J-30 Delivery Points to Continued Progress for Lockheed’s TACAMO Mission, Investors Watch for Follow-ThroughThe Apex TimesBusinessMastercard pushes a stablecoin-ready payments “switchboard,” aiming to make crypto rails easier for banksThe Apex TimesBusinessLockheed Martin’s missile backlog and new PAC-3 Edge interceptor add momentum as investors weigh valuationThe Apex TimesBusinessEli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader marketThe Apex TimesBusinessTSMC warns AI chip demand still outpaces supply, reigniting focus on Nvidia’s role in the buildoutThe Apex TimesBusinessBlackRock Investors Weigh How Private Markets and Active ETFs Could Change Fee StreamsThe Apex TimesBusinessMag 7 roundup spotlights Tesla Roadster timeline, Nvidia’s “space AI” push and Microsoft’s Nadella security warningThe Apex Times
Back to front
OmniAb signs global collaboration and license agreement with Eli Lilly for ion channel program
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 17, 6:29 AM EDT

OmniAb signs global collaboration and license agreement with Eli Lilly for ion channel program

The small-cap discovery technology company OmniAb said it has entered a global collaboration and licensing arrangement tied to an ion channel therapeutic program with Eli Lilly (LLY). Details on economics and timelines were not provided in the announcement cited by the market news post.

By The Apex Times Newsroom2 min readAI-assisted Apex article

OmniAb, Inc. said it has reached a global collaboration and license agreement with Eli Lilly & Company for an ion channel therapeutic program. The announcement, dated August 17, 2026, positions the deal as part of OmniAb’s effort to pair its discovery research platform with large pharmaceutical development and commercialization capabilities.

The company did not describe the specific ion channel target, the program stage, or the geographic scope of the parties’ responsibilities in the market news post. It also did not disclose financial terms, such as upfront payments, milestone targets, royalty rates, or cost-sharing arrangements, in the information available for this story.

OmniAb is described as a provider of discovery research technology intended to enable the discovery of next-generation therapeutics. In that framing, the collaboration with Eli Lilly is likely aimed at translating early-stage biology and candidate discovery into a development path for a therapeutically relevant ion channel mechanism, though the announcement did not spell out the workflow steps.

Ion channels are membrane proteins that regulate electrical indicates in cells, and they are a common drug target area across neuroscience, cardiology, and other therapeutic categories. Targeting an ion channel can be attractive because small-molecule and biologic approaches can potentially modulate channel activity to change disease-relevant indicating, but developing such drugs typically requires tight control of selectivity and safety.

For Eli Lilly, deals of this type typically support its broader pipeline strategy by adding externally sourced programs that can be moved through preclinical and clinical development if the biology holds up. Even without details, a global collaboration implies that Lilly expects to play a sustained role beyond licensing alone, aligning incentives across discovery and development phases.

OmniAb’s prior emphasis on discovery technology suggests the company is trying to monetize platform value through partnerships with larger industry players. The announcement’s use of “global collaboration and license” also indicates both parties may share responsibilities for certain activities, followed by rights to commercialize the resulting intellectual property.

As of the publication of the referenced market news post, key deal specifics remain undisclosed. Investors will likely be looking for additional disclosure from OmniAb or Lilly that clarifies the program’s target and stage, the scope of rights granted, and any milestones or royalties that could affect future revenue recognition and cash flow.

Next, watch for whether OmniAb provides further detail in a company release or filing, including the ion channel indication or target, the research-to-development handoff plan, and any financial structure such as upfront, milestones, or royalties, as well as whether Lilly’s pipeline updates begin to reflect the program.

Why It Matters

  • Partnerships with large pharma can accelerate the development of early discovery programs, but market disclosures about deal structure often determine the near-term financial impact.
  • Ion channel programs can represent high-value therapeutic opportunities, yet they require substantial validation work, so program stage and target information are material to risk assessment.
  • The “global collaboration and license” language suggests Eli Lilly may have ongoing involvement across discovery-to-development rather than a narrow rights transaction, but the scope was not disclosed.

Sources

Key Facts

  • OmniAb announced a global collaboration and license agreement with Eli Lilly for an ion channel program.
  • The announcement referenced by the market news post was dated August 17, 2026.
  • The market post described OmniAb as a provider of discovery research technology for next-generation therapeutics.
  • The announcement, as captured in the market news post, did not provide financial terms or deal economics.
  • The specific ion channel target and program stage were not detailed in the information available for this story.

Healthcare Related

OmniAb signs global collaboration and license agreement with Eli Lilly for ion channel program | The Apex Times